Drugs / Young TIL
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01585415 | Apr 2012 → Jul 2016 | melanoma, metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02621021 | Dec 2015 → Jun 2028 expected | melanoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02133196 | Oct 2014 → Oct 2027 expected | adenocarcinoma, adenosquamous carcinoma, non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT01993719 | Dec 2013 → Oct 2021 | metastatic melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01585428 | Apr 2012 → Apr 2016 | anus cancer, cervical cancer, oropharyngeal carcinoma, penile cancer +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01319565 | Mar 2011 → Sep 2024 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Young TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585428 ↗ |
| Modality | Cell therapy | “Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL)” NCT01585415 ↗ |
| Route | Intravenous | “Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.” NCT01319565 ↗ |